Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial

Next Previous
X
Search
Trial Profile

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis. A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Fibrosis; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 19 Dec 2023 Results post hoc analysis included data from a subset of patients (N=251) with biopsy confirmed NASH and fibrosis stage F1-F3 ; comparing the evaluation of histological features of non-alcoholic steatohepatitis (NASH) between pathologists and a machine learning (ML) pathology model, published in the Hepatology
    • 14 Nov 2023 Results of post-hoc exploratory analysis of digital quantification of the collagen proportionate area (CPA) compared in the total biopsy area and non-steatotic liver tissue (fat-free CPA) following semaglutide treatment for NASH, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Jun 2023 Data from 3 studies were taken from NCT03357380, NCT02970942 & NCT03987451 assessing the impact of T2D and other cardiometabolic parameters on weight loss presented at the European Association for the Study of the Liver Congress 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top